Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany

TL;DR

This study shows that dupilumab treatment for atopic dermatitis leads to significant improvement in symptoms over two years in routine care.

Contribution

The study provides one of the largest 2-year follow-up datasets on dupilumab's effectiveness in real-world atopic dermatitis treatment.

Findings

78.8% of patients achieved a 75% improvement in Eczema Area and Severity Index (EASI 75) at 24 months.

51.2% of patients achieved a 90% improvement in EASI (EASI 90) at 24 months.

Results are based on the HOME core outcome set, enhancing standardization in eczema research.

Abstract

The TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date. We report the Harmonising Outcome Measures for Eczema (HOME) core outcome set. The Eczema Area Severity Index (EASI) 75 and EASI 90 response rates for patients on treatment at month 24 were 78.8% and 51.2%, respectively.